Prosecution Insights
Prosecution Insights
11 pending office actions • 6 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §103 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 58.2% | +64.5% |
| WARD, AARON DUREL | 1 | — | — |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 58.9% | +34.1% |
| ZAHORIK, AMANDA MARY | 1 | 56.3% | +49.1% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| GROOMS, TIFFANY NICOLE | 1 | 59.1% | +46.3% |
| JONES-FOSTER, ERICA NICOLE | 1 | 50.0% | +47.5% |
| MONTANARI, DAVID A | 1 | 64.7% | +49.1% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 33.3% | +78.6% |
| ALLEN, SARAH ELIZABETH | 1 | 60.9% | +45.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16202955 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS RHODOPSIN GENE | SHIN, DANA H | 6d |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 68d |
| 18257176 | BIALLELIC KNOCKOUT OF TRAC | BRETZ, COREY LANE | 70d |
| 18291051 | HEPATITIS B VIRUS (HBV) KNOCKOUTS | KONOPKA, CATHERINE ANNE | — |
| 18264552 | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 CRISPR NUCLEASE | ZAHORIK, AMANDA MARY | — |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | — |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 68d |
| 18291051 | HEPATITIS B VIRUS (HBV) KNOCKOUTS | KONOPKA, CATHERINE ANNE | — |
| 18264552 | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 CRISPR NUCLEASE | ZAHORIK, AMANDA MARY | — |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | — |
| 18296798 | NOVEL OMNI-50 CRISPR NUCLEASE | JONES-FOSTER, ERICA NICOLE | — |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | — |
| 17775017 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE USING GUIDES 21-30 NUCLEOTIDES IN LENGTH | HUMPHRIES, NICHOLAS ADAM | — |
| 17607690 | NOVEL OMNI CRISPR NUCLEASES | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1635 | 2 |
| 1637 | 2 |
| 1656 | 1 |
| 1632 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291051 | HEPATITIS B VIRUS (HBV) KNOCKOUTS | KONOPKA, CATHERINE ANNE | — | §102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18251667 | NOVEL OMNI-50 CRISPR NUCLEASE-RNA COMPLEXES | WARD, AARON DUREL | 1636 | §102§112DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18551817 | COMPOSITIONS AND METHODS FOR TREATING HYPERCHOLESTEROLEMIA | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112 | Non-Final OA | 68d | Pending | Sep 21, 2023 |
| 18264552 | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 CRISPR NUCLEASE | ZAHORIK, AMANDA MARY | 1636 | §101§102§112 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18257176 | BIALLELIC KNOCKOUT OF TRAC | BRETZ, COREY LANE | 1635 | §101§102 | Non-Final OA | 70d | Pending | Jun 13, 2023 |
| 18249950 | NOVEL OMNI 56, 58, 65, 68, 71, 75, 78, AND 84 CRISPR NUCLEASES | GROOMS, TIFFANY NICOLE | 1637 | §101§102§103 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 18296798 | NOVEL OMNI-50 CRISPR NUCLEASE | JONES-FOSTER, ERICA NICOLE | 1656 | Other | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17927658 | BIALLELIC KNOCKOUT OF SARM1 | MONTANARI, DAVID A | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 23, 2022 |
| 17775017 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS ELANE GENE USING GUIDES 21-30 NUCLEOTIDES IN LENGTH | HUMPHRIES, NICHOLAS ADAM | 1631 | DP | Final Rejection | — | Pending | May 06, 2022 |
| 17607690 | NOVEL OMNI CRISPR NUCLEASES | ALLEN, SARAH ELIZABETH | 1637 | §103 | Final Rejection | — | Pending | Oct 29, 2021 |
| 16202955 | DIFFERENTIAL KNOCKOUT OF AN ALLELE OF A HETEROZYGOUS RHODOPSIN GENE | SHIN, DANA H | 1635 | §103§112Other | Non-Final OA | 6d | Pending | Nov 28, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial